Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 10:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 186 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: %5 dextrose for infusion Clear all
Completed Phase 2 Interventional Results available

A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer

NCT00992186
View directory record Official record
Conditions
Prostate Cancer
Interventions
Carlumab
Drug
Lead sponsor
Centocor Research & Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Orange City, Florida • Ann Arbor, Michigan • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Sep 30, 2026, 10:37 PM EDT
Recruiting Phase 1 Interventional

HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors

NCT05861895
View directory record Official record
Conditions
Solid Tumors, Adult
Interventions
HF158K1 / 1.4 g lipid dose, HF158K1 / 2.2 g lipid dose, HF158K1 / 2.9 g lipid dose
Drug
Lead sponsor
HighField Biopharmaceuticals Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Sep 30, 2026, 10:37 PM EDT
Not listed Phase 1Phase 2 Interventional

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

NCT02061800
View directory record Official record
Conditions
Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions
CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide, Alemtuzumab, Tacrolimus, Melphalan, Busulfan, Fludarabine, Methylprednisolone
Device · Drug
Lead sponsor
Diane George
Other
Eligibility
Up to 22 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Sep 30, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

Clofarabine Bone Marrow Cytoreduction

NCT00724009
View directory record Official record
Conditions
Leukemia
Interventions
Clofarabine
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Sep 30, 2026, 10:37 PM EDT
Completed Phase 2 Interventional

DUR-928 in Patients With Alcoholic Hepatitis

NCT03917407
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
DUR-928 (Moderate AH), DUR-928 (Severe AH)
Drug
Lead sponsor
Craig James McClain
Other
Eligibility
21 Years to 67 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Sep 30, 2026, 10:37 PM EDT
Completed Not applicable Interventional Results available

The Effect of the Hyperinsulinemic Normoglycemic Clamp on Myocardial Function and Utilization of Glucose

NCT01187329
View directory record Official record
Conditions
Hyperglycemia, Aortic Valve Replacement, Aortic Stenosis, Cardiac Surgery
Interventions
hyperinsulinemic normoglycemic clamp (HNC), control group
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years to 84 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Sep 30, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

NCT03541603
View directory record Official record
Conditions
Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
Interventions
Levosimendan, Matching Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
16
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 30, 2026, 10:37 PM EDT
Terminated Phase 2 Interventional Results available

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma

NCT02062359
View directory record Official record
Conditions
Metastatic Cancer, Metastatic Melanoma
Interventions
Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells, Aldesleukin, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2016 · Synced Sep 30, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

Milrinone in Congenital Diaphragmatic Hernia

NCT02951130
View directory record Official record
Conditions
Congenital Diaphragmatic Hernia, Persistent Pulmonary Hypertension of the Newborn, Hypoxemic Respiratory Failure, Pulmonary Hypoplasia
Interventions
Milrinone, Placebo (5% Dextrose)
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
0 Hours to 168 Hours
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Sep 30, 2026, 10:37 PM EDT
Completed Phase 4 Interventional Results available

Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT00867932
View directory record Official record
Conditions
Hemoglobinuria, Paroxysmal
Interventions
Eculizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Orange, California • Pensacola, Florida • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Sep 30, 2026, 10:37 PM EDT
Completed Phase 1 Interventional

CD-NP in Subjects With Stable Chronic Heart Failure

NCT00620308
View directory record Official record
Conditions
Stable Chronic Heart Failure
Interventions
CD-NP, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Sep 30, 2026, 10:37 PM EDT
Active, not recruiting Phase 2 Interventional

FDOPA PET and Nutritional Support in Parkinson's Disease

NCT04459052
View directory record Official record
Conditions
Parkinson Disease, Idiopathic Parkinson Disease
Interventions
N acetyl cysteine, [F-18] Fluorodopa Positron Emission Tomography
Dietary Supplement · Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
30 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Sep 30, 2026, 10:37 PM EDT
Completed Not applicable Interventional

Effect of Physiologic Insulin Administration on Cognition

NCT06424652
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Blood draws, Hyperinsulinemic Euglycemic Clamp Technique Insulin Sensitivity test, Resting Metabolic Rate (RMR)
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
65 Years to 75 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Sep 30, 2026, 10:37 PM EDT
Terminated Phase 2 Interventional Results available

Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

NCT02111863
View directory record Official record
Conditions
Melanoma, Skin Cancer
Interventions
Aldesleukin, Fludarabine, Cyclophosphamide, 4-1BB Selected Tumor Infiltrating Lymphocytes (TIL)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Sep 30, 2026, 10:37 PM EDT
Terminated Phase 2 Interventional Results available

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

NCT01814046
View directory record Official record
Conditions
Metastatic Ocular Melanoma, Metastatic Uveal Melanoma
Interventions
Aldesleukin, Cyclophosphamide, Fludarabine, Young Tumor Infiltrating Lymphocytes (TIL)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 30, 2026, 10:37 PM EDT
Completed Phase 3 Interventional

Automated Insulin Delivery for Inpatients With Dysglycemia

NCT06418880
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
AID system with Remote Real-Time CGM, Standard of Care Insulin Therapy + CGM
Device · Combination Product
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
3
States / cities
Stanford, California • Atlanta, Georgia • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Sep 30, 2026, 10:37 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Reversing Glucose and Lipid-mediated Vascular Dysfunction

NCT04832009
View directory record Official record
Conditions
Blood Pressure, Hypertension
Interventions
Dextrose 20 % in 500 ML Injection, Intralipid, Saline, Ascorbic acid
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 79 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Sep 30, 2026, 10:37 PM EDT
Terminated Not applicable Interventional Results available

The Effect of Lactation on Insulin Sensitivity and Lipolysis in Women

NCT04146909
View directory record Official record
Conditions
GDM, Lactation
Interventions
Hyperinsulinemic-euglycemic clamp
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Sep 30, 2026, 10:37 PM EDT
Completed Phase 4 Interventional Results available

A Multiple Myeloma Trial in Patients With Bone Metastases

NCT00104104
View directory record Official record
Conditions
Multiple Myeloma
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
68
States / cities
Huntsville, Alabama • Glendale, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2011 · Synced Sep 30, 2026, 10:37 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Identifying the Brain Substrates of Hypoglycemia Unawareness in Type 1 Diabetes

NCT02866435
View directory record Official record
Conditions
Hypoglycemia
Interventions
Insulin, Glucose, Potassium phosphate
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 30, 2026, 10:37 PM EDT
Completed Not applicable Interventional Results available

IV Insulin Protocol in Diabetes and Renal Transplantation

NCT00609986
View directory record Official record
Conditions
Kidney Transplantation, Diabetes, Hyperglycemia
Interventions
insulin, NPH Insulin or glargine insulin and aspartame insulin
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2013 · Synced Sep 30, 2026, 10:37 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Setrusumab vs Placebo for Osteogenesis Imperfecta

NCT05125809
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Setrusumab, Placebo
Biological · Other
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
5 Years to 25 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
23
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Sep 30, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Brain Ketone Metabolism in Type 1 Diabetes

NCT02471040
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia
Interventions
Beta-hydroxybutyrate, Normal Saline
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Sep 30, 2026, 10:37 PM EDT
Completed Not applicable Interventional Results available

Dietary Glycemic Index, Brain Function and Food Intake in Patients With Type 1 Diabetes Mellitus

NCT02772783
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
high GI meal, low GI meal, euglycemic insulin clamp, primed-variable insulin infusion
Other · Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Sep 30, 2026, 10:37 PM EDT